You are here:
TOXICOGENOMICS DRUG DISCOVERY AND THE PATHOLOGIST
Citation:
Boorman, G. A., S. P. Anderson, W. M. Casey, R. H. Brown, L. M. Crosby, K. Gottschalk, M. Easton, H. Ni, AND K. T. Morgan. TOXICOGENOMICS DRUG DISCOVERY AND THE PATHOLOGIST. TOXICOLOGIC PATHOLOGY 30(1):15-27, (2001).
Description:
Toxicogenomics, drug discovery, and pathologist.
The field of toxicogenomics, which currently focuses on the application of large-scale differential gene expression (DGE) data to toxicology, is starting to influence drug discovery and development in the pharmaceutical industry. Toxicological pathologists, who play key roles in the development of therapeutic agents, have much to contribute to DGE studies, especially in the experimental design and interpretation phases. The intelligent application of DGE to drug discovery can reveal the potential for both desired (therapeutic) and undesired (toxic) responses. The pathologist's understanding of anatomic, physiologic, biochemical, immune and other underlying factors that drive mechanisms of tissue responses to noxious agents turns a bewildering 'array' of gene expression data into focused research programs. The latter process is critical for the successful application of DGE to toxicology. Pattern recognition is a useful first step, but mechanistically based DGE interpretation is where the long-term future of these new technologies lies. Pathologists trained to carry out such interpretations will become important members of the research teams needed to successfully apply these technologies to drug discovery and safety assessment. As a pathologist using DGE, you will need to learn to 'read DGE data' in the same way you learned to read glass slides, patiently and with a desire to learn and later to teach. In return, you will gain a greater depth of understanding of cell and tissue function, both in health and disease.